MedTrace Logo

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

NCT01590979 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-03-23

Study results available
· View outcomes & findings →

Summary

The aim of this study is to evaluate the prophylactic effects of Ranolazine on new onset atrial fibrillation in post-operative coronary artery bypass graft and valve surgery patient population at Staten Island University hospital.

Conditions

  • Atrial Fibrillation New Onset
  • Hemorrhage
  • Prolonged QTc Interval
  • Ventricular Tachycardia
  • Medical Care; Complications, Late Effect of Complications

Interventions

DRUG

Ranolazine

1000mg, two times a day, 12 hour intervals

DRUG

Placebo

two times a day, 12 hour intervals

Sponsors & Collaborators

Principal Investigators

  • Soad Bekheit, MD · Staten Island University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01590979 on ClinicalTrials.gov